In odd aftermath of FDA Commissioner Mark McClellan’s lecture, NCI Director Andrew von Eschenbach forwards the commissioner’s thank-you note to 3,000 NCI staff. The email blast follows FDA’s return of NCI’s gift to McClellan.
Also in this 8-page issue: NCI informatics project caBIG will “rapidly accelerate” cancer research, von Eschenbach says.
NCI plans 18 percent budget cuts for large R01s, smaller cuts to other research project grants. NCI treatment division director Ellen Feigal accepts position with Translational Genomics Research Institute in Phoeniz, Ariz.
In the cancer centers: San Antonio Cancer Institute gets a new director, funding commitments.
UT Health Science Center dedicates new Children’s Cancer Research Institute.
Funding opportunities listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says
